Sulfuric Acid — predicted protein targets

Known targets — ChEMBL curated mechanism

ADRA1A ADRA1B ADRA1D ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 ADRB3 CALCRL CHRM1 CHRM2 CHRM3 F2R MAOA MAOB MAP2K1 MAP2K2 NTRK1 NTRK2 NTRK3 OPRD1 OPRK1 OPRM1 P2RY12 PKLR SCN10A SCN11A SCN1A SCN2A SCN3A SCN4A SCN5A SCN7A SCN8A SCN9A SLC18A2 SLC6A2 SLC6A3 TLR7 TLR9 TUBA1A TUBA1B TUBA1C TUBA3C TUBA3E TUBA4A TUBB TUBB1 TUBB2A TUBB2B TUBB3 TUBB4A TUBB4B TUBB6 TUBB8 dacA dacB dacC folA ftsI mrcA mrcB mrdA pol rplA rplB rplC rplD rplE rplF rplI rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmB1 rpmB2 rpmC rpmD rpmE rpmE2 rpmF rpmG rpmG1 rpmG2 rpmH rpmI rpmJ rpmJ2 rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsR1 rpsR2 rpsS rpsT rpsU rpsZ ykgM ykgO

The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	TSHR	P16473	5/20	0.65

▸	LMNA	P02545	1/20	0.65

▸	KMT2A	Q03164	3/20	0.56

▸	HTT	P42858	2/20	0.56

▸	GAA	P10253	1/20	0.56

▸	CES2	O00748	1/20	0.56

▸	CES1	P23141	1/20	0.56

▸	ALDH1A1	P00352	5/20	0.55

▸	TDP1	Q9NUW8	1/20	0.55

▸	ALOX15	P16050	1/20	0.55

▸	CA2	P00918	2/20	0.53

▸	CA5A	P35218	1/20	0.53

▸	CA1	P00915	1/20	0.53

▸	MMP1	P03956	1/20	0.53

▸	MMP2	P08253	1/20	0.53

▸	MMP9	P14780	1/20	0.53

▸	MMP8	P22894	1/20	0.53

▸	MMP13	P45452	1/20	0.53

▸	ACHE	P22303	1/20	0.50

▸	TP53	P04637	1/20	0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL13815840	0.92	TSHR (0.77)	TSHRLMNAKMT2AHTTGAA
Dinitrophenylene SCHEMBL34066	0.92	TSHR (0.77)	TSHRLMNAKMT2AHTTGAA
SCHEMBL9733865	0.90	TSHR (0.74)	TSHRLMNAKMT2AHTTGAA
Dinitrophenylene SCHEMBL11883873	0.88	TSHR (0.71)	TSHRLMNAKMT2AHTTGAA
Dinitrophenylene SCHEMBL28595103	0.84	TSHR (0.71)	TSHRLMNAKMT2AHTTGAA
Dinitrophenylene SCHEMBL9798067	0.84	TSHR (0.71)	TSHRLMNAKMT2AHTTGAA
Sulfuric Acid SCHEMBL10617886	0.82	CYP19A1 (0.50)	TSHRLMNAKMT2AHTTGAA
Dinitrophenylene SCHEMBL28091203	0.81	TSHR (0.90)	TSHRLMNAKMT2AHTTGAA
Dinitrophenylene SCHEMBL36632	0.81	TSHR (1.00)	TSHRLMNAKMT2AHTTGAA
SCHEMBL17347353	0.81	TSHR (0.55)	TSHRLMNAKMT2AHTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20250025469-A1	COMBINATION THERAPIES	INFINITY PHARMACEUTICALS, INC.	2025-01-23	—	—	US	disclosed
US-20240325398-A1	COMBINATION THERAPIES	INFINITY PHARMACEUTICALS, INC.	2024-10-03	—	—	US	disclosed
US-11944631-B2	Combination therapies	INFINITY PHARMACEUTICALS, INC. (US)	2024-04-02	—	—	US	disclosed
US-20220125794-A1	COMBINATION THERAPIES	INFINITY PHARMACEUTICALS, INC.	2022-04-28	—	—	US	disclosed
US-11110096-B2	Combination therapies	INFINITY PHARMACEUTICALS, INC. (US)	2021-09-07	—	—	US	disclosed
US-20210088520-A1	TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE	SERVIER PHARMACEUTICALS LLC	2021-03-25	—	—	US	disclosed
US-20200338083-A1	COMBINATION THERAPIES	INFINITY PHARMACEUTICALS, INC.	2020-10-29	—	—	US	disclosed
CN-105622756-B	L OX and L OX L2 inhibitors and application thereof	吉利德生物制剂公司	2020-07-28	—	—	CN	disclosed
US-20190025313-A1	TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE	SERVIER PHARMACEUTICALS LLC	2019-01-24	—	—	US	disclosed
US-20180371551-A1	MAT2A INHIBITORS FOR TREATING MTAP NULL CANCER	SERVIER PHARMACEUTICALS LLC	2018-12-27	—	—	US	disclosed
EP-0494135-A1	DETECTION AND QUANTIFICATION OF -i(NEU) RELATED PROTEINS IN THE BIOLOGICAL FLUIDS OF HUMANS.	ONCOGENETICS PARTNERS (US)	1992-07-15	—	—	EP	disclosed
EP-0471825-A1	PTPase DIAGNOSTICS AND USES THEREOF	APPLIED BIOTECHNOLOGY, INC. (US)	1992-02-26	—	—	EP	disclosed
WO-1991017764-A1	IMMUNOGENIC PEPTIDES, ANTIBODIES AND USES THEREOF RELATING TO CD4 RECEPTOR BINDING	DANA FARBER CANCER INSTITUTE (US)	1991-11-28	—	—	WO	disclosed
EP-0453560-A1	LOCALIZATION AND CHARACTERIZATION OF THE WILMS'S TUMOR GENE	MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US)	1991-10-30	—	—	EP	disclosed
WO-1991013173-A1	PTPase DIAGNOSTICS AND USES THEREOF	APPLIED BIOTECHNOLOGY, INCORPORATED (US)	1991-09-05	—	—	WO	disclosed
EP-0411018-A4	DETECTION, QUANTITATION AND CLASSIFICATION OF RAS PROTEINS IN BODY FLUIDS AND TISSUES	—	1991-08-21	—	—	EP	disclosed
WO-1991007509-A1	LOCALIZATION AND CHARACTERIZATION OF THE WILMS'S TUMOR GENE	MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US)	1991-05-30	—	—	WO	disclosed
WO-1991005264-A1	DETECTION AND QUANTIFICATION OF NEU RELATED PROTEINS IN THE BIOLOGICAL FLUIDS OF HUMANS	ONCOGENETICS PARTNERS (US)	1991-04-18	—	—	WO	disclosed
EP-0411018-A1	DETECTION, QUANTITATION AND CLASSIFICATION OF RAS PROTEINS IN BODY FLUIDS AND TISSUES.	DU PONT (US)	1991-02-06	—	—	EP	disclosed
WO-1989010565-A1	DETECTION, QUANTITATION AND CLASSIFICATION OF RAS PROTEINS IN BODY FLUIDS AND TISSUES	E.I. DU PONT DE NEMOURS AND COMPANY (US)	1989-11-02	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20250025469-A1	COMBINATION THERAPIES	BCL2, BAK1, BCL3	TSHR 4453/4885LMNA 2557/4885KMT2A 2618/4885
US-20200338083-A1	COMBINATION THERAPIES	HDAC1, HDAC4, HDAC2	TSHR 2771/4885LMNA 2976/4885KMT2A 343/4885
US-20220125794-A1	COMBINATION THERAPIES	BCL2, BAK1, BCL3	TSHR 4453/4885LMNA 2557/4885KMT2A 2618/4885
US-11944631-B2	Combination therapies	BCL2, BAK1, BCL3	TSHR 4453/4885LMNA 2557/4885KMT2A 2618/4885
US-20180371551-A1	MAT2A INHIBITORS FOR TREATING MTAP NULL CANCER	MAT2A, MNAT1, MAT2B	TSHR 3173/4885LMNA 2607/4885KMT2A 26/4885
US-20190025313-A1	TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE	DHODH, IDH1, IDH3A	TSHR 4042/4885LMNA 4346/4885KMT2A 1847/4885
US-20240325398-A1	COMBINATION THERAPIES	HDAC1, HDAC4, HDAC2	TSHR 2771/4885LMNA 2976/4885KMT2A 343/4885
US-11110096-B2	Combination therapies	BCL2, BAK1, BCL3	TSHR 4453/4885LMNA 2557/4885KMT2A 2618/4885
US-20210088520-A1	TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE	DHODH, IDH1, IDH3A	TSHR 4042/4885LMNA 4346/4885KMT2A 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.